KBC Group NV Acquires 730 Shares of Insmed Incorporated (NASDAQ:INSM)

KBC Group NV lifted its holdings in shares of Insmed Incorporated (NASDAQ:INSM) by 20.4% in the third quarter, according to its most recent filing with the SEC. The firm owned 4,310 shares of the biopharmaceutical company’s stock after acquiring an additional 730 shares during the period. KBC Group NV’s holdings in Insmed were worth $315,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in INSM. V Square Quantitative Management LLC bought a new position in Insmed during the third quarter worth about $30,000. EntryPoint Capital LLC acquired a new stake in Insmed in the 1st quarter valued at $33,000. GAMMA Investing LLC grew its position in Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 224 shares during the period. First Horizon Advisors Inc. raised its stake in Insmed by 83.4% during the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 287 shares in the last quarter. Finally, Exchange Traded Concepts LLC raised its stake in Insmed by 522.5% during the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 627 shares in the last quarter.

Insmed Price Performance

Shares of INSM stock opened at $73.72 on Wednesday. The firm’s 50 day moving average price is $72.03 and its two-hundred day moving average price is $65.26. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $80.53. The stock has a market cap of $13.19 billion, a PE ratio of -13.28 and a beta of 1.12.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The firm had revenue of $93.40 million during the quarter, compared to analyst estimates of $93.36 million. During the same quarter in the prior year, the company earned ($1.10) EPS. The firm’s revenue was up 18.1% compared to the same quarter last year. As a group, analysts forecast that Insmed Incorporated will post -5.42 EPS for the current year.

Insider Activity

In other Insmed news, insider Michael Alexander Smith sold 27,871 shares of the stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $74.35, for a total value of $2,072,208.85. Following the completion of the sale, the insider now directly owns 67,856 shares in the company, valued at $5,045,093.60. This represents a 29.12 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Martina M.D. Flammer sold 13,436 shares of Insmed stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $74.92, for a total value of $1,006,625.12. Following the transaction, the insider now owns 106,134 shares in the company, valued at $7,951,559.28. This trade represents a 11.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 78,882 shares of company stock valued at $5,765,446 in the last ninety days. 4.60% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a research report on Monday, September 9th. StockNews.com downgraded Insmed from a “hold” rating to a “sell” rating in a report on Friday, August 9th. JPMorgan Chase & Co. raised their price target on Insmed from $72.00 to $74.00 and gave the company an “overweight” rating in a report on Thursday, October 3rd. HC Wainwright reiterated a “buy” rating and issued a $90.00 price objective on shares of Insmed in a research report on Friday, November 1st. Finally, UBS Group increased their target price on Insmed from $78.00 to $84.00 and gave the stock a “buy” rating in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $83.07.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.